Skip to main content

Ciphergen and Nasdaq Exchange Resolve Dispute

NEW YORK, Jan.24, (GenomeWeb News) - The "E" appended to Ciphergen's ticker symbol will be gone tomorrow as the company has been informed by Nasdaq National Market officials that it has "evidenced compliance" in listing requirements, Ciphergen said today.

 

As GenomeWeb News reported last week, the Nasdaq questioned Ciphergen's July 2005 stock sale to Quest, suggesting that the deal "constituted a change of control which required shareholder approval" because the deal could result in Quest's owning more than 20 percent of the total outstanding shares. Ciphergen replied that Quest would not own more than 19.9 percent of Ciphergen.

 

Ciphergen declined to comment on the resolution of the dispute.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.